APA (7th ed.) Citation

H, E., P, M., N, B., M, B., L, V., L, K., . . . MV, M. (2026). Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Advances in therapy, 43(1), 333. https://doi.org/10.1007/s12325-025-03409-y

Chicago Style (17th ed.) Citation

H, Einsele, et al. "Comparative Efficacy of Talquetamab Vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 Vs. LocoMMotion/MoMMent." Advances in Therapy 43, no. 1 (2026): 333. https://doi.org/10.1007/s12325-025-03409-y.

MLA (9th ed.) Citation

H, Einsele, et al. "Comparative Efficacy of Talquetamab Vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 Vs. LocoMMotion/MoMMent." Advances in Therapy, vol. 43, no. 1, 2026, p. 333, https://doi.org/10.1007/s12325-025-03409-y.